The U.S. Food and Drug Administration made a groundbreaking announcement in June 2025, approving lenacapavir (Yeztugo) for use as a twice-yearly PrEP injection that provided nearly 100% protection in trials. This revolutionary treatment represents a major advancement in HIV prevention, offering a convenient and highly effective alternative to daily medication regimens.
The new long-acting injectable drug addresses one of the biggest challenges in HIV prevention: maintaining consistent treatment adherence. These long-acting preventive drugs aren’t just about convenience; they offer a public health advantage. Reducing the number of missed doses can mean reducing transmission at scale.
The approval comes at a crucial time, as researchers continue making progress toward finding a cure for HIV. They may also help overcome structural barriers to access and adherence, especially in underserved communities. This breakthrough positions lenacapavir as a real improvement for populations where daily or frequent dosing schedules are difficult to maintain, potentially transforming HIV prevention strategies globally.
Source: https://www.labiotech.eu/in-depth/hiv-cure-research/